Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
BIO International 2022: Words from Space and Venus
Bio International was finally back for 2022. What did our first-timer to the event make of it?
Biotech terrain may be tricky, but it’s worth persevering
What are venture capitalists looking for from the biotech and pharma space?
Five reasons you can’t ignore payers during pipeline development
Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in…
ASCO 2022 Preview
ASCO 2022 kicks off this week, and a few days ago the abstracts for most of the presentations dropped.
Late to the party? Prepare to pay the price
I saw a tweet recently asking “in recent years, what has become simultaneously worse and more expensive?”. One wag responded with “life”, but I’d also argue that…
Networking on the Agenda at LSX World Congress
This week saw the return of the LSX World Congress in a real-life environment (London, to be precise).
Orphan drugs: about as niche as a flat white
To those beyond the world of biopharma, the term “orphan drug” sounds a bit sad, a bit forgotten. But to those involved in the industry, the superior return on…
Genetic Medicine: The Next Gene-eration
Once upon a time, a gene therapy player could release data on a handful of subjects and see its share price rocket. The sector was riding high after the landmark…